Pupovac Stevan S, Hemli Jonathan M, Scheinerman S Jacob, Hartman Alan R, Brinster Derek R
Department of Cardiovascular and Thoracic Surgery, North Shore University Hospital/Northwell Health, Manhasset, New York.
Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York.
Int J Angiol. 2021 Jul 30;30(4):292-297. doi: 10.1055/s-0041-1729860. eCollection 2021 Dec.
Aortic procedures are associated with higher risks of bleeding, yet data regarding perioperative transfusion in this patient population are lacking. We evaluated transfusion patterns in patients undergoing proximal aortic surgery to provide a benchmark against which future standards can be assessed. Between June 2014 and July 2017, 247 patients underwent elective aortic reconstruction for aneurysm. Patients with acute aortic syndrome, endocarditis, and/or prior cardiac surgery were excluded. Transfusion data were analyzed by type of operation: ascending aorta replacement ± aortic valve procedure (group 1, = 122, 49.4%); aortic root replacement with a composite valve-graft conduit ± ascending aorta replacement (group 2, = 93, 37.7%); valve-sparing aortic root replacement (VSARR) ± ascending aorta replacement (group 3, = 32, 13.0%). Thirty-day mortality for the entire cohort was 2.02% (5 deaths). Overall, 75 patients (30.4%) did not require any transfusion of blood or other products. Patients in groups 1 and 3 were significantly more likely to avoid transfusion than those in group 2. Mean transfusion volume for any individual patient was modest; those who underwent VSARR (group 3) required less intraoperative red blood cells (RBC) than others. Intraoperative transfusion of RBC was independently associated with an increased risk of death at 30 days. Elective proximal aortic reconstruction can be performed without the need for excessive utilization of blood products. Composite root replacement is associated with a greater need for transfusion than either VSARR or isolated replacement of the ascending aorta.
主动脉手术出血风险较高,但目前缺乏该患者群体围手术期输血的数据。我们评估了接受近端主动脉手术患者的输血模式,以提供一个可用于评估未来标准的基准。在2014年6月至2017年7月期间,247例患者因动脉瘤接受了择期主动脉重建手术。排除患有急性主动脉综合征、心内膜炎和/或既往心脏手术史的患者。根据手术类型分析输血数据:升主动脉置换术±主动脉瓣手术(第1组,n = 122,49.4%);使用复合瓣膜移植物管道进行主动脉根部置换术±升主动脉置换术(第2组,n = 93,37.7%);保留瓣膜的主动脉根部置换术(VSARR)±升主动脉置换术(第3组,n = 32,13.0%)。整个队列的30天死亡率为2.02%(5例死亡)。总体而言,75例患者(30.4%)不需要输注任何血液或其他制品。第1组和第3组的患者比第2组的患者更有可能避免输血。任何个体患者的平均输血量适中;接受VSARR(第3组)的患者术中所需红细胞(RBC)比其他患者少。术中输注RBC与30天死亡风险增加独立相关。择期近端主动脉重建手术无需过度使用血液制品即可进行。与VSARR或单纯升主动脉置换相比,复合根部置换术对输血的需求更大。